Alpha-lipoic_JJ
acid_NN
is_VBZ
a_DT
potent_JJ
inhibitor_NN
of_IN
NF-kappa_NN
B_NN
activation_NN
in_IN
human_JJ
T_NN
cells_NNS
._.

Acquired_VBN
immunodeficiency_NN
syndrome_NN
-LRB-_-LRB-
AIDS_NN
-RRB-_-RRB-
results_VBZ
from_IN
infection_NN
with_IN
a_DT
human_JJ
immunodeficiency_NN
virus_NN
-LRB-_-LRB-
HIV_NN
-RRB-_-RRB-
._.

The_DT
long_JJ
terminal_JJ
repeat_NN
-LRB-_-LRB-
LTR_NN
-RRB-_-RRB-
region_NN
of_IN
HIV_NN
proviral_JJ
DNA_NN
contains_VBZ
binding_VBG
sites_NNS
for_IN
nuclear_JJ
factor_NN
kappa_NN
B_NN
-LRB-_-LRB-
NF-kappa_NN
B_NN
-RRB-_-RRB-
,_,
and_CC
this_DT
transcriptional_JJ
activator_NN
appears_VBZ
to_TO
regulate_VB
HIV_NN
activation_NN
._.

Recent_JJ
findings_NNS
suggest_VBP
an_DT
involvement_NN
of_IN
reactive_JJ
oxygen_NN
species_NNS
-LRB-_-LRB-
ROS_NN
-RRB-_-RRB-
in_IN
signal_NN
transduction_NN
pathways_NNS
leading_VBG
to_TO
NF-kappa_NN
B_NN
activation_NN
._.

The_DT
present_JJ
study_NN
was_VBD
based_VBN
on_IN
reports_NNS
that_IN
antioxidants_NNS
which_WDT
eliminate_VBP
ROS_NN
should_MD
block_VB
the_DT
activation_NN
of_IN
NF-kappa_NN
B_NN
and_CC
subsequently_RB
HIV_NN
transcription_NN
,_,
and_CC
thus_RB
antioxidants_NNS
can_MD
be_VB
used_VBN
as_IN
therapeutic_JJ
agents_NNS
for_IN
AIDS_NN
._.

Incubation_NN
of_IN
Jurkat_NN
T_NN
cells_NNS
-LRB-_-LRB-
1_CD
x_CC
10_CD
6_CD
cells\/ml_NNS
-RRB-_-RRB-
with_IN
a_DT
natural_JJ
thiol_NN
antioxidant_NN
,_,
alpha-lipoic_JJ
acid_NN
,_,
prior_JJ
to_TO
the_DT
stimulation_NN
of_IN
cells_NNS
was_VBD
found_VBN
to_TO
inhibit_VB
NF-kappa_NN
B_NN
activation_NN
induced_VBN
by_IN
tumor_NN
necrosis_NN
factor-alpha_NN
-LRB-_-LRB-
25_CD
ng\/ml_NN
-RRB-_-RRB-
or_CC
by_IN
phorbol_NN
12-myristate_NN
13-acetate_NN
-LRB-_-LRB-
50_CD
ng\/ml_NN
-RRB-_-RRB-
._.

The_DT
inhibitory_JJ
action_NN
of_IN
alpha-lipoic_JJ
acid_NN
was_VBD
found_VBN
to_TO
be_VB
very_RB
potent_JJ
as_IN
only_RB
4_CD
mM_NN
was_VBD
needed_VBN
for_IN
a_DT
complete_JJ
inhibition_NN
,_,
whereas_IN
20_CD
mM_NN
was_VBD
required_VBN
for_IN
N-acetylcysteine_NN
._.

These_DT
results_NNS
indicate_VBP
that_IN
alpha-lipoic_JJ
acid_NN
may_MD
be_VB
effective_JJ
in_IN
AIDS_NN
therapeutics_NNS
._.

